Adicet Bio

Adicet Bio is a clinical-stage biotechnology company based in Redwood City, California, discovering and developing off-the-shelf allogeneic gamma delta T cell therapies engineered with chimeric antigen receptors for autoimmune diseases and cancer, alongside a preclinical in vivo CAR-T platform. Its lead candidate, prula-cel (formerly ADI-001), is an anti-CD20 CAR gamma delta T cell therapy being developed in systemic lupus erythematosus with or without lupus nephritis; on September 28, 2026 the company reported updated Phase 1 data from 22 efficacy-evaluable patients showing 54% DORIS remission at 12 months and complete renal response in 50% of evaluable lupus nephritis patients after a single dose off immunosuppression, with no cases of IEC-HS and no ICANS, and said it expects to begin a pivotal study in the fourth quarter of 2026. Its second program, ADI-212, is an anti-CD70 CAR gamma delta T cell therapy with an FDA-cleared IND in metastatic castration-resistant prostate cancer and a Phase 1 study expected to initiate in the fourth quarter of 2026.